Danaher (NYSE:DHR) Cut to Hold at Wall Street Zen

Danaher (NYSE:DHR) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research firms have also recently commented on DHR. UBS Group lowered their target price on Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Wednesday. Argus set a $265.00 target price on Danaher in a research note on Wednesday, January 14th. Rothschild & Co Redburn set a $205.00 target price on Danaher in a research note on Friday, April 17th. Jefferies Financial Group reaffirmed a “buy” rating and set a $245.00 price objective on shares of Danaher in a research report on Tuesday. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a research report on Thursday, January 29th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $242.45.

Danaher Trading Down 0.7%

DHR opened at $177.31 on Friday. The stock has a market cap of $125.49 billion, a PE ratio of 34.30, a PEG ratio of 2.42 and a beta of 0.95. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The business has a 50 day moving average of $195.75 and a 200-day moving average of $213.86. Danaher has a 52 week low of $175.00 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 21st. The conglomerate reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.88 EPS. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Equities research analysts predict that Danaher will post 8.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Gregory M. Milosevich sold 1,320 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the completion of the transaction, the executive vice president owned 5,099 shares of the company’s stock, valued at $1,060,642.99. This trade represents a 20.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Root Financial Partners LLC increased its holdings in shares of Danaher by 97.3% in the 1st quarter. Root Financial Partners LLC now owns 1,953 shares of the conglomerate’s stock worth $370,000 after purchasing an additional 963 shares in the last quarter. Capital Asset Advisory Services LLC increased its holdings in shares of Danaher by 4.3% in the 1st quarter. Capital Asset Advisory Services LLC now owns 14,755 shares of the conglomerate’s stock worth $2,885,000 after purchasing an additional 609 shares in the last quarter. Essex Financial Services Inc. increased its holdings in shares of Danaher by 15.6% in the 1st quarter. Essex Financial Services Inc. now owns 6,284 shares of the conglomerate’s stock worth $1,191,000 after purchasing an additional 849 shares in the last quarter. CHICAGO TRUST Co NA increased its holdings in shares of Danaher by 55.5% in the 1st quarter. CHICAGO TRUST Co NA now owns 10,624 shares of the conglomerate’s stock worth $2,014,000 after purchasing an additional 3,791 shares in the last quarter. Finally, Balentine LLC increased its holdings in shares of Danaher by 5.4% in the 1st quarter. Balentine LLC now owns 4,507 shares of the conglomerate’s stock worth $855,000 after purchasing an additional 232 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Guggenheim reiterated a Buy rating on Danaher, supporting demand-side interest from institutional buyers. Guggenheim Reaffirms Buy
• Positive Sentiment: An analyst price-target lift to $232 signals buy-side upside vs. current levels, which can support the stock if investors focus on medium-term earnings guidance. Price Target Raised to $232
• Neutral Sentiment: Danaher priced ~€3.0 billion of euro-denominated senior notes across maturities (2028–2038). This raises liquidity for operations or M&A but increases long-term debt on the balance sheet. Senior Notes Offering
• Neutral Sentiment: Coverage pieces question whether the recent share weakness makes DHR an attractive value play — useful for long-term investors but not an immediate catalyst. Valuation Article
• Negative Sentiment: Danaher agreed to settle shareholder litigation tied to its post‑pandemic outlook for about $172.5M, a direct hit to cash and a reminder of past forecasting issues; that likely pressured sentiment. Settlement Report
• Negative Sentiment: Short interest rose ~17.8% to 8.18M shares as of April 15 (≈1.3% of float; short-interest ratio ~2.5 days), indicating increased speculative/hedged bearish positioning that can amplify downward moves.
• Negative Sentiment: Morgan Stanley trimmed its price target (from $270 to $255), and UBS issued a pessimistic forecast—both moves add analyst-driven downside pressure despite differing target levels. Morgan Stanley PT Cut UBS Forecast
• Negative Sentiment: Analysts/commentary flag Danaher’s Masimo acquisition as adding long-term potential but creating near-term margin and integration pressure, a nearer-term risk to earnings momentum. Masimo Deal Commentary

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.